Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

La Roche sur Yon, France Clinical Trials

A listing of La Roche sur Yon, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (31) clinical trials

Tepotinib Phase II in Non-small Cell Lung Cancer (NSCLC) Harboring MET Alterations

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer. This study will also measure a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the ...

Phase

0.0 miles

Learn More »

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment that would have the theoretical advantage of being well tolerated and more effective than chemotherapy alone even after an anti-aromatase therapy.

Phase

0.0 miles

Learn More »

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

National multicentric phase II trial evaluating whether single agent cetuximab is effective as maintenance therapy after 8 cycles of first line FOLFIRI plus cetuximab in mCRC patients with KRAS and NRAS wild-type genes, assessed by progression-free survival at 6 months after start of maintenance therapy.

Phase

0.0 miles

Learn More »

Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers

The aflibercept-5-FU combination has never been evaluated as yet. Aflibercept, at a dose of 4 mg/kg, has already been used in combination with 5-FU at the doses used in the simplified LV5FU2 regimen (folinic acid 400 mg/m2 IV in 90 min, then 5-FU 400 mg/m2 IV bolus on D1, followed ...

Phase

0.0 miles

Learn More »

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

The purpose of the OPTIPRIME phase II non-randomised study is to evaluate the efficacy and tolerability of the combination of FOLFOX plus panitumumab according to a "stop and go" strategy. If disease control is achieved while on induction treatment, oxaliplatin and panitumumab will be stopped after the sixth cycle; a ...

Phase

0.0 miles

Learn More »

Phase 2 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Phase 2 randomized, placebo controlled study assessing the efficacy (complete recovery from AKI) and safety of Reltecimod in patients with suspected or confirmed abdominal sepsis (planned or completed surgical (laparotomy or laparoscopy) or interventional radiologic procedures for control of underlying abdominal infection within 24 hours of evaluation by medical personnel), ...

Phase

0.0 miles

Learn More »

PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo

The major therapeutic challenge in patient with Atopic Dermatitis is long-term control of disease activity (LTC), for which the current TAT-based pro-active strategy does not meet all the needs. Phototherapy is a good candidate: it is widely used as a second-line treatment in AD with demonstrated efficacy. However, only short-term ...

Phase

0.0 miles

Learn More »

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

This study will take place in several periods and phases of treatment: Observational period of selection of 28 days maximum Treatment period constituted: a first phase of treatment with ibrutinib alone (28 days): pre-phase, a formal protocol phase during which the two study drugs (ibrutinib and daratumumab) will be used ...

Phase

0.0 miles

Learn More »

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na ve Metastatic Kidney Cancer

Research Hypothesis: Molecular groups of ccrcc will define patients who will respond to nivolumab alone, nivolumab combined with ipilimumab, or VEGFR-TKI (sunitinib or pazopanib) in subjects with previously untreated metastatic renal cell carcinoma (mRCC). Conditions Advanced or metastatic RCC: previously untreated in metastatic setting. Frozen tumor samples available for molecular ...

Phase

0.0 miles

Learn More »

SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer

SAFIR PI3K is an open-label multicenter phase II randomized trial, comparing alpelisib plus fulvestrant to maintenance chemotherapy in patient PIK3CA mutated with HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy. The primary objective is to determine whether treatment with ...

Phase

0.0 miles

Learn More »